Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Karo Pharma AB M&A Activity 2017

May 4, 2017

6166_iss_2017-05-04_7e847570-883a-486d-ab55-27d5e8c8dbc1.pdf

M&A Activity

Open in viewer

Opens in your device viewer

Karo Pharma - Pfizer Collaboration reaches second milestone

STOCKHOLM, May 4, 2017

Karo Pharma has received a milestone for the RORgamma project amounting to 2 million USD.

"This is the second milestone-payment for RORgamma. Very good news for the project" says Anders Lönner, Chairman of the Board.

For further information, please contact: Henrik Palm, CFO, Telephone +46 70 540 40 14 or E-mail [email protected]

The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on May 4, 2016 at 3.00 p.m. CET.